Showing results (81-90 of 94) with videos related to
Sort By:
Pageof 10
Cells|March 29, 2023
Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint InhibitorsCarlo Genova, Roberta Tasso, Alessandra Rosa, et al.Clinical and Experimental Medicine|August 6, 2024
Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumabCarlo Genova, Silvia Marconi, Giovanna Chiorino, et al.Lung Cancer (Amsterdam, Netherlands)|April 5, 2016
BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational studyTiziana Vavalà, Alessandro Follador, Marcello Tiseo, et al.Clinical Lung Cancer|June 25, 2017
Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE StudySara Pilotto, Antonio Rossi, Tiziana Vavalà, et al.Journal for Immunotherapy of Cancer|February 1, 2023
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817Neal E Ready, Clarisse Audigier-Valette, Jonathan W Goldman, et al.Thoracic Cancer|December 23, 2021
Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapyGiuseppe L Banna, Marcello Tiseo, Diego L Cortinovis, et al.Cancer Treatment and Research Communications|February 26, 2026
Real-life management of stage III non-small cell lung cancer patients in Italy: the BE-PACIFIC observational studyPaolo Bironzo, Alessandro Morabito, Sonia Silipigni, et al.Cancer Immunology, Immunotherapy : CII|August 31, 2021
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuationMarco Russano, Alessio Cortellini, Raffaele Giusti, et al.European Journal of Cancer (Oxford, England : 1990)|November 19, 2020
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic indexSebastiano Buti, Melissa Bersanelli, Fabiana Perrone, et al.The Oncologist|July 26, 2026
EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the 'Rebiopsy on osi' Study)Eleonora Gariazzo, Francesca Colamartini, Ornella Cantale, et al.Pageof 10